Acute drug reactions associated with the novel targeted therapies used in treating skin cancer
|
|
- Suzan Fields
- 5 years ago
- Views:
Transcription
1 Acute drug reactions associated with the novel targeted therapies used in treating skin cancer Dr Rishika Sinha Consultant Dermatologist Chelsea & Westminster Hospital NHS Foundation Trust West Middlesex University Hospital
2 Aims Talk about common skin toxicities with newer targeted agents used to treat melanoma skin cancers: BRAF MEK Vemurafenib (Zelboraf) Dabrafenib (Tafinlar) Trametinib (Mekinist) Immunotherapies Ipilimumab (Yervoy) PD1 Pembroluzimab (Keytudra) Nivolumiab (Opdivo)
3 Targeted therapies Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecules involved in tumour growth and progression. In melanoma, certain genetic mutations promote the growth of the tumour: BRAF (50%), NRAS (20%) c-kit (2-5%) Davies et al. Nature. 2002;417:949-54
4 Other targeted therapies Aswell as Targeted therapies, Immunotherapy can be considered a form of targeted therapy specifically targeting the immune system IPILUMMUAB NIVOLUMAB
5 Targeted therapies in Melanoma BRAF inhibitors Vemurafenib licensed in February 2012 Dabrafenib MEK inhibitors Often in combination with BRAF inhibitors Ipilimumab Anti PD1 C Kit inhibitors
6 Why are skin toxicities relevant? Skin toxicities can cause significant discomfort and distress to the patient Considerable impact on overall QOL (anybody who has come across an eczema or psoriasis sufferer can tell you that first hand) Can lead to early cessation of anti-cancer treatment Unfamiliarity with skin toxicities may lead to physician doubt, therefore causing unnecessary interruptions (or at worst, cessation) in treatment
7 Manageable side effects Counselling Early recognition Management of skin side effects can lead to treatment success
8 BRAF inhibitors vemurafenib dabrafenib
9 NRAS BRAF Proto-oncogene Critical serine/threonine Activated by somatic mutation V600E RAF BRAF V600E MEK ERK Abnormal Cellular Cellular Proliferation
10 NRAS Vemurafenib Dabrafenib Potent BRAF inhibitor Oral therapy BRAF V600E MEK ERK Abnormal Normal cellular Cellular Proliferation
11 Vemurafenib
12
13 Skin toxicities with Vemurafenib Our experience at the Marsden Studied 107 patients retrospectively Looked at common skin toxicities When they occurred Management
14 Adverse event Male : female ratio, n (%) Mean time to Rash 28 (54) : 24 (46) onset, days Adverse-event treatment and dose modifications applied Grade 1 21 (81) : 5 (19) 60 No additional treatment required or managed with emollients. None required systemic corticosteroids Grade 2 6 (30) : 14 (70) 12 Four patients required treatment interruption and restarted at 720 mg twice daily Grade 3 1 (20) : 4 (80) 11 All patients had treatment interruption and restarted at a lower dose. Three patients were treated with prednisolone mg Photosensitivity 19 (59) : 13 (41) 53 Grade 1 11(55) : 9 (45) 49 Grade 2 6 (67) : 3 (33) 48 Grade 3 1 (100) : Folliculitis 6 (100) : 0 83 Three patients required treatment with lymecycline Dry skin 11 (58) : 8 (42) 68 All patients were treated with emollients Keratoacanthoma or squamous-cell carcinoma Squamoproliferative growths 9 (56) : 7 (44) 97 Majority surgically excised; 1 patient received topical 5-fluorouracil 19 (54) : 16 (46) 79 ± 74 All patients were treated with cryotherapy Erythema nodosum 0 : 7 (100) 44 Two patients required systemic corticosteroids mg Hyperkeratosis 8 (47) : 9 (53) 76 ± 44 Treated with urea-containing emollient (Flexitol, LaCorium Health UK, Milton Keynes, UK); pedicure provided symptomatic relief Alopecia 13 (43) : 17 (57) 89 ± 41 No effective treatment available Milia 0 : 3 (100) 89 ± 68 No effective treatment available
15 Rash
16 Vemurafenib related toxicity: Management of Skin Toxicities Grade 1 Grade 2 Macular / Papular or Perifollicular Eruption No symptoms Macular / Papular or Perifollicular Eruption With symptoms (itching or soreness) <50% skin surface Observation, emollients Antihistamines, emollients If persistent refer to Dermatologist and consider topical steroids, Elocon or Betnovate ointment If intolerable consider dose reduction Emollients Shampoos soap substitutes/bath additives Dermal 500, Balneum plus water base Doublebase, Cetraben ointments Epaderm, 50:50 WSP:LP Dermax or Capasal twice weekly Antihistamines SEDATING : Hydroxyzine 25-50mg nocte (do not use if driving) NON SEDATING: Cetirizine 10-40mg od, Fexofenadine 180 mg od
17 Vemurafenib related toxicity: Management of Skin Toxicities Grade 3 Macular / Papular Eruption or Perifollicular With symptoms (itching or soreness) + >50% skin surface Refer to Dermatologist Antihistamines, emollients, topical steroids; Elocon or Dermovate Consider oral steroids: Prednisolone 0.5mg/kg od x 5-7d (max of 60mg/day) Hold Vemurafenib until <grade 1 then restart at lower dose (720mg to 480mg bd) Grade 4 Stevens Johnson/Toxic epidermal necrolysis (widespread red skin with peeling or blister formation + mucosal involvement) Admission IV fluids and electrolytes Discontinue Vemurafenib Call Dermatologist for opinion, advise treatment and skin biopsy
18 Summary of Rash Mean time to onset 32 days into treatment Folliculocentric eruption typical ( goose bumps ) Distribution - Limbs and trunk Be aware of the rash that blisters. 1 case of TEN.
19 Photosensitivity
20 Photosensitivity Almost all of the patients initially enrolled to the BRIM 3 study developed photosensitive reactions to vemurafenib Within 15 minutes of exposure Chest, arms, face and feet within 1-2 weeks of starting the drug Patients reported-phototoxic symptoms indoors and driving Phototoxic risk remains throughout course of treatment
21 Management of phototoxicity Similar to sunburn Emollients Topical steroids Avoid and cover-up SPF and UVA rating 5* sun protection cream 1 patient required oral prednisolone, break of 17 days and dose reduction by 25%
22 Squamoproliferative lesions
23 Squamous papillomas, KA and SCC Proliferative growths on the skin KA and SCC classified as cancerous growths Skin type 1 2 Older patients Photo-damaged skin Mean time to onset 92 days Can be eruptive Once they have occurred effects are not repetitive
24 Management - Squamous papillomas, KA and SCC Refer to Dermatologist Small, irritating squamous papillomas Cryotherapy (liquid nitrogen) Keratoacanthoma / squamous cell carcinoma Excision/currettage suspected KA/SCC Efudix, Aldara Acitretin
25 Hyperkeratosis
26 Hyperkeratosis - feet Very problematic - painful Interferes with walking In one patient treatment break of one week necessary Hyperkeratosis may also be manifested as plantar verrucae
27 Management Analgesia Emulsiderm soaks Diprosalic salicylic acid with topical steroid Dermovate under occlusion Flexitol heel balm / urea containing emollients (calmurid, Eucerin)
28 Rare stuff
29 Radiation recall Acute inflammatory reaction confined to previously irradiated areas and triggered by the administration of precipitating systemic agents weeks to years after the radiation treatment Common agents: gemcitabine, docetaxol, etoposide, doxorubicin, vemurafenib
30 Management algorithm of BRAF-related skin side effects Sinha et al British Journal of Dermatology 2012, 167, p
31
32 Dabrafenib Side effects similar to Vemurafenib Differences however include: Grover s disease (27%) No photosensitivity Pyrexia Anforth et al. Cutaneous manifestations of dabrafenib (GSK ): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. BrJ Dermatol
33 Grover s management No curative treatment Topical steroids eumovate, betnovate Moisturisers cetraben, diprobase Keep cool 2% menthol in aqueous cream Trial course of tetracyclines
34 Summary -BRAFi Skin side effects are common SE manageable and patients should remain on drug if possible Hypothesis - the adverse drug effects are primarily secondary to an upregulation of an alternative signalling pathway rather than a true hypersensitivity response. RASopathic - cutaneous side effects of BRAF inhibitors simulate some of the cutaneous findings seen in patients with germline RAS mutations e.g. cardiofaciocutaneous (CFC) syndrome
35 Summary -BRAFi Close collaboration with Dermatologists can prolong treatment course Advise regular skin checks Early recognition and prophylactic advice on photosensitivity essential Dabrafenib can be good alternative for patients intolerant of skin side effects of Vemurafenib
36 MEK inhibitors
37 Adverse events associated with TRAMETINIB therapy
38 Management of MEK inhibitor rashes At outset Topical emollients Sun screen Clindamycin topical solution 1% Consider lymecycline bd or doxycycline 100mg BD Grade 1 Add in topical steroids : Elocon or Betnovate ointment Grade 2 Continue systemic antibiotics Increase Topical steroids : Dermovate, Dermovate NN Stop topical antibiotic
39 Management of MEK inhibitor rashes If rash progresses to Grade 3 Interrupt treatment Continue same topical treatment and systemic antibiotic (lymecycline or doxycycline) Consider short term oral steroid (0.5 to 1 mg/kg for 7 days) if very severe rash OR, if extensive infection, change oral antibiotics; consider IV s 1.If grade 1 or 2 rash is considered tolerable by the patient, treatment can be continued at the same dosing with supportive treatment (level 1 topical steroids and antibiotics) 2. If grade 1 or 2 rash is considered not tolerable by the patient despite maximal supportive treatment, treatment can be transitory interrupted (management as in grade 3)
40 Summary MEK inhibitors The clinical spectrum of cutaneous lesions observed resembles the known cutaneous toxicities that occur with EGFR inhibitors. Inhibition of the MAPK signaling pathway in keratinocytes appears to result in similar side effects either by blockade of the EGF receptor or the MEK kinase.
41 Summary MEK inhibitors Additionally depigmentation of scalp hair occurs as has already been observed in therapy with c-kit inhibitors. Oedema is a significant problem (seen with other TKI s) Management of skin toxicities very similar to EGFRI s
42 Immunotherapy ipilimumab nivolumab
43 Ipilumumab Ipilimumab is a fully human monoclonal antibody (IgG1) that blocks CTLA-4 to promote antitumor immunity Recently used to treat patients with un-resectable metastatic melanoma Associated with significant side effects
44 Most frequent immune-related adverse events with Ipilumumab Ipilumumab 3mg/kg* Dermatological 43.5% 1-2% grade 3 Gastrointestinal 29% Colitis 7.6% (5.3% grade 3) Endocrine 7.6% Hepatic 3.8% 29% Ipilumumab 10mg/kg (plus Dacarbazine)# 49% 3.2% grade % Colitis 4.5% (1.6% grade 3) *Hodi FS, O'Day SJ, McDermott DF, et al. N Engl J Med Aug 19;363(8): Improved survival with ipilimumab in patients with metastatic melanoma. #Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med Jun 30;364(26):
45 Ipilimumab-related toxicity: Management of Skin Toxicities Grade 1 Grade 2 Grade 3 Grade 4 Macular / Papular Eruption No symptoms Symptoms (Pruritus) <50% skin surface Symptoms + >50% skin surface Generalised, exfoliative, ulcerative, bullous dermatitis Observation If persistent consider antihistamines (see box below) Antihistamines If persistent consider steroids; either topical if localised rash (Dermovate cream bd) systemic for more extensive rash (Prednisolone 1mg/kg od x 3d, maximum of 60mg/day) Antihistamines Oral steroids: Prednisolone 1mg/kg od x 5-7d (max of 60mg/day) Hold ipilimumab until <grade 2 Admission IV fluids and electrolytes Hydrocortisone IV 100mg QDS once rash controlled taper over > 1 month Permanent discontinuation of ipilimumab Refer to Dermatologist may need skin biopsy and advise treatment Antihistamines Clorphenamine maleate (Piriton ) 4mg every 6-8 hours. Duration: Causes drowsiness do not use if driving Until all skin lesions Cetirizine 10mg od have disappeared Loratadine 10mg od The Royal Marsden Hospital Sept 2010
46 Ipilimumab Vemurafenib Sensitivity Skin Reaction after Ipilimumab N Engl J Med 2012; 366: March 1, patients treated within 4 weeks of stopping Ipilimumab 4 (31%) developed grade 3 reaction within 6 to 8 days Grade 3 rash was reported in only 7 to 8% of patients treated in phase 2 and phase 3 trials Not responsive to glucocorticoids All responded to a treatment break and re-started at a lower dose
47 Nivolumab Pembrolizumab Not as many skin side effects observed Vitiligo in KEYNOTE-001 study
48 c-kit inhibitors c KIT (CD117) a tyrosine kinase receptor Mutated in up to 10% of acral and mucosal melanomas (5% of all melanomas caucasians, 70% in Asian population) and those melanomas arising in chronically sun damaged skin Nilotinib (NICAM study at the Marsden) 20% developed skin rash
49 Summary Cutaneous toxicities associated with the newer targeted anticancer agents Rapidly advancing field Significant cutaneous toxicities Develop good management algorithms Side effects are generally tolerable Combination therapies will be standard of care
50
17/01/2017. ckit NRAS BRAF MEK ERK. ANTITUMOR IMMUNE RESPONSE PROLIFERATION
BRAF inhibitors: vemurafenib (Zelboraf ) dabrafenib (Tafinlar ) Universitair Ziekenhuis Gent MEK inhibitors: cobimetinib trametinib(mekinist ) selumetinib CUTANEOUS SIDE EFFECTS OF BRAF-INHIBITORS Lieve
More informationApproaches To Treating Advanced Melanoma
Approaches To Treating Advanced Melanoma Suraj Venna, MD Medical Director, Melanoma and Cutaneous Oncology Inova Schar Cancer Institute Associate Professor, VCU Fairfax VA Disclosures No relevant disclosures
More informationCutaneous reactions to targeted therapies. Stavonnie Patterson, MD, FAAD Northwestern University Feinberg School of Medicine March 6, 2017
Cutaneous reactions to targeted therapies Stavonnie Patterson, MD, FAAD Northwestern University Feinberg School of Medicine March 6, 2017 Disclosures I have no relevant disclosures Papulopustular Eruption
More informationEGFR inhibitors. EGFR inhibitors. Cutaneous side effects of EGFRinhibitors. EGFR inhibitor skin toxicity. EGFR is abundantly expressed in the skin
TARGETED THERAPIES AND THEIR CUTANEOUS TOXICITIES Brussels, 14/1/2017 Cutaneous side effects of EGFRinhibitors and their management Siegfried Segaert Dermatology Dept University Hospital Leuven Belgium
More informationOPTIMAL MANAGEMENT OF IMMUNE- RELATED ADVERSE EVENTS ASSOCIATED WITH CHECKPOINT INHIBITORS
OPTIMAL MANAGEMENT OF IMMUNE- RELATED ADVERSE EVENTS ASSOCIATED WITH CHECKPOINT INHIBITORS Alberto Fusi Charité Comprehensive Cancer Centre Berlin, Germany 1 Immune check point blockade with CTLA-4, anti-pd-1
More informationBCCA Protocol Summary for the Treatment of BRAF V600 Mutation- Positive Unresectable or Metastatic Melanoma using vemurafenib and cobimetinib
BCCA Protocol Summary for the Treatment of BRAF V600 Mutation- Positive Unresectable or Metastatic Melanoma using vemurafenib and cobimetinib Protocol Code Tumour Group Contact Physician USMAVVC Skin and
More informationBRAF Inhibition in Melanoma
BRAF Inhibition in Melanoma New York City, Mar 22-23, 2013 Bartosz Chmielowski, MD, PhD Assistant Clinical Professor University of California Los Angeles Disclosures Speaker Bureau: BMS, Genentech, Prometheus
More informationSkin cancer is the most common
Section Editors: Christopher J. Campen and Beth Eaby-Sandy Vemurafenib: First-in-Class BRAF- Mutated Inhibitor for the Treatment of Unresectable or Metastatic Melanoma LINDSAY SHELLEDY, PharmD, and DANIELLE
More informationMelanoma: From Chemotherapy to Targeted Therapy and Immunotherapy. What every patient needs to know. James Larkin
Melanoma: From Chemotherapy to Targeted Therapy and Immunotherapy What every patient needs to know James Larkin Melanoma Therapy 1846-2017 Surgery 1846 Cytotoxic Chemotherapy 1946 Checkpoint Inhibitors
More informationModern therapy in oncology Metastatic melanoma
Modern therapy in oncology Metastatic melanoma Anna Buda-Nowak Oncology Department; University Hospital in Cracow Melanoma Malignant skin neoplasm derived from neuroectodermal melanomatous cells. The incidence:
More informationTargeted Therapies in Melanoma
Mutations and Targets Targeted Therapies in Melanoma ckit NRAS
More informationSkin Side Effects U N I V E R S I T Y OF V I E N N A, D E P A R T M E N T OF O N C O L O G Y, G E N E R A L H O S P I T A L V I E N N A
Skin Side Effects Christiane Thallinger, M D U N I V E R S I T Y OF V I E N N A, D E P A R T M E N T OF O N C O L O G Y, G E N E R A L H O S P I T A L V I E N N A Targets Substances 1 Multi Kinase Inhibitors
More informationNCCP Chemotherapy Regimen. Vemurafenib Monotherapy
INDICATIONS FOR USE: Vemurafenib Monotherapy INDICATION ICD10 Regimen Code *Reimbursement Indicator Treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. C43
More informationWhat You Need to Know about Advanced Melanoma Therapies Targeted Approaches
2018 AAD Annual Meeting, San Diego, CA What You Need to Know about Advanced Melanoma Therapies Targeted Approaches Susan M. Swetter, MD, FAAD Professor of Dermatology Director, Pigmented Lesion & Melanoma
More informationVemurafenib (Zelboraf ) BRAF V600 mutation positive Metastatic Melanoma
Vemurafenib (Zelboraf ) BRAF V600 mutation positive Metastatic Melanoma Background: Vemurafenib has been approved by NICE for the treatment of BRAF V600 mutation positive unresectable or metastatic melanoma.
More informationErlotinib Non-Small Cell Lung Cancer
Systemic Anti Cancer Treatment Protocol Erlotinib Non-Small Cell Lung Cancer PROTOCOL REF: MPHAERLLU (Version No: 1.0) Approved for use in: First line treatment of locally advanced or metastatic epidermal
More informationAdvances in Melanoma
Advances in Melanoma The Blue, the Black and the Ugly 1 Outline History of Melanoma Why be concerned? Skin cancer updates What s old? What s new (and why are Skin Tumor Group med oncs excited again)? What
More informationThe Development of Encorafenib (LGX818) and Binimetinib (MEK162) in Patients With Metastatic Melanoma
The Development of Encorafenib (LGX818) and Binimetinib (MEK162) in Patients With Metastatic Melanoma Reinhard Dummer, 1 Keith Flaherty, 2 Richard Kefford, 3 Paolo A. Ascierto, 4 Laure Moutouh-de Parseval,
More informationDermatology GP Referral Guidelines
Austin Health Dermatology Department holds 5 Clinic sessions to discuss and plan the treatment of with Dermatology conditions. Department of Health clinical urgency categories for specialist clinics Urgent:
More informationMelanoma: Early Detection and Therapeutic Progress
Melanoma: Early Detection and Therapeutic Progress David W. Ollila, MD Professor of Surgery Jesse and James Millis Professor of Surgery Thanks to my collaborators, mentors and patients May 19, 2017 Disclosures:
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal (STA) Dabrafenib for treating unresectable, advanced or metastatic
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal (STA) Dabrafenib for treating unresectable, advanced or metastatic BRAF V600 mutation-positive melanoma mutation-positive melanoma
More informationSignificance. Outline and Objectives. S007 Systemic Therapies for Medical Oncology
S007 Systemic Therapies for Medical Oncology Anisha B. Patel, M.D. Assistant Professor, Dermatology UT MD Anderson Cancer Center UT Health Science Center Houston Safety considerations Outline and Objectives
More informationNormal RAS-RAF (MAPK) pathway signaling
BRAF-Mutations in Melanomas L. Mazzucchelli Istituto Cantonale di Patologia, Locarno 77. Annual Meeting Swiss Society of Pathology, Lucerne 2011 Sponsored by Roche Pharma Switzerland Melanoma has increased
More informationUpdate on Targeted Therapy in Melanoma
Update on Targeted Therapy in Melanoma Seville June 2013 James Larkin FRCP PhD London UK Overview What are the targets in melanoma? BRAF / KIT / NRAS / GNAQ / MEK DNA / microtubules CTLA4 / PD1 / PDL1
More informationDermatologists & Oncologists: Two important reasons we are getting closer. Ioanna Panoutsopoulou, MD. GAMC June 1 st 2016
Dermatologists & Oncologists: Two important reasons we are getting closer Ioanna Panoutsopoulou, MD GAMC June 1 st 2016 Points of presentation Cutaneous adverse events from: Epidermal Growth Factor Receptor
More informationMelanoma- Fighting the Dark Side
Melanoma- Fighting the Dark Side Anna C. Pavlick, BSN, MSc, DO, MBA Professor of Medicine and Dermatology Director, NYU Melanoma Program Director, NYU Clinical Trials Office NYU Perlmutter Cancer Center
More informationMultikinase inhibitors: Multikinase inhibitors: Regorafenib skin toxicity. Cutaneous side effects of multikinase-inhibitors and their management
TARGETED THERAPIES AND THEIR CUTANEOUS TOXICITIES Brussels, 14/1/2017 Cutaneous side effects of multikinase-inhibitors and their management Siegfried Segaert Dermatology Dept. Uinversity Hospital Leuven
More informationERLOTINIB (TARCEVA ) FOR NSCLC
DRUG ADMINISTRATION SCHEDULE Day Cycle length Drug Daily Dose Route Schedule Days 1 to 28 Continuous Erlotinib 150 mg Oral ONCE daily DOSE FORM Presented as 25mg, 100mg and 150mg Tablets CYCLE LENGTH AND
More informationNew paradigms for treating metastatic melanoma
New paradigms for treating metastatic melanoma Paul B. Chapman, MD Melanoma Clinical Director Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center, New York 20 th Century Overall
More informationLung Pathway Group Afatinib in Non-Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Afatinib in Non-Small Cell Lung Cancer (NSCLC) Indication: NICE TA310 First line treatment option in locally advanced or metastatic NSCLC Positive test for epidermal growth factor receptor
More informationNECN Chemotherapy Handbook Protocol
DRUG ADMINISTRATION SCHEDULE Day Cycle length Drug Daily Dose Route Schedule Days 1 to 28 Continuous Erlotinib 150 mg Oral ONCE daily DOSE FORM Presented as 25mg, 100mg and 150mg Tablets CYCLE LENGTH AND
More informationBCCA Protocol Summary for the Treatment of BRAF V600 Mutation- Positive Unresectable or Metastatic Melanoma Using dabrafenib and Trametinib
BCCA Protocol Summary for the Treatment of BRAF V600 Mutation- Positive Unresectable or Metastatic Melanoma Using dabrafenib and Protocol Code Tumour Group Contact Physician USMAVDT Skin and Melanoma Dr.
More informationPEMBROLIZUMAB (KEYTRUDA ) for the treatment of advanced melanoma or previously treated NSCLC
DRUG ADMINISTRATION SCHEDULE Day Drug Dose Route Diluent Rate Day 1 Pembrolizumab 2mg/kg IV Infusion 100mL 0.9% Sodium Chloride* Or 100mL 5% Glucose* *Final concentration must be between 1 to 10mg/mL Over
More informationIdentifying and managing dermatologic toxicities associated with EGFR-inhibitor therapy. An educational resource for healthcare professionals
Identifying and managing dermatologic toxicities associated with EGFR-inhibitor therapy An educational resource for healthcare professionals What to expect from EGFR-inhibitor therapy The goal of EGFR-inhibitor
More information11 PROTOCOL NO. 11: Psoracomb (UVB TL01) protocol PROTOCOL NO. 12: MPD protocol 23 Appendix 25
Classification: Policy Lead Author: Tsui Ling Consultant Dermatologist, Clinical Additional author(s): N/A Authors Division: Dermatology Unique ID: GSCDerm02(13) Issue number: 3 Expiry Date: September
More informationBlack is the New Black or How I learned to stop worrying and love melanoma (with apologies to Dr. Strangelove)
Black is the New Black or How I learned to stop worrying and love melanoma (with apologies to Dr. Strangelove) Provincial Cancer Care Conference 2018 Ralph P.W. Wong MD FRCPC St Boniface Site Director
More informationProspective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib
670368CMSXXX10.1177/1203475416670368Journal of Cutaneous Medicine and SurgeryLacroix and Wang research-article2016 Original Article Prospective Case Series of Cutaneous Adverse Effects Associated With
More informationMetastatic Melanoma. Cynthia Kwong February 16, 2017 SUNY Downstate Medical Center Department of Surgery Grand Rounds
Metastatic Melanoma Cynthia Kwong February 16, 2017 SUNY Downstate Medical Center Department of Surgery Grand Rounds Case Presentation 77 year old male with previous history of scalp melanoma and thyroid
More informationEmerging Trends & Strategies in the Treatment & Management of Metastatic Melanoma. Evan J. Lipson, MD
Emerging Trends & Strategies in the Treatment & Management of Metastatic Melanoma Evan J. Lipson, MD Johns Hopkins University School of Medicine Sidney Kimmel Comprehensive Cancer Center April 25, 2014
More informationINIBITORE di BRAF nel MELANOMA
INIBITORE di BRAF nel MELANOMA Paola Agnese Cassandrini Negrar,29 novembre 2016 BRAF is a serine/threonine protein kinasi encoded on chromosome 7q34 that activates the MAP kinase/erksegnaling pathway
More informationIpilimumab (skin) Indication Advanced (unresectable or metastatic) melanoma in patients who have received prior therapy.
Ipilimumab (skin) Indication Advanced (unresectable or metastatic) melanoma in patients who have received prior therapy. (NICE TA268) ICD-10 codes Codes prefixed with C43 Regimen details Day Drug Dose
More informationImmunotherapy Treatment Developments in Medical Oncology
Immunotherapy Treatment Developments in Medical Oncology A/Prof Phillip Parente Director Cancer Services Eastern Health Executive MOGA ATC Medical Oncology RACP www.racpcongress.com.au Summary of The Desired
More informationvemurafenib 240mg film-coated tablet (Zelboraf ) SMC No. (792/12) Roche Products Ltd.
Resubmission vemurafenib 240mg film-coated tablet (Zelboraf ) SMC No. (792/12) Roche Products Ltd. 08 November 2013 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationInnovations in Immunotherapy - Melanoma. Systemic Therapies October 27, 2018 Charles L. Bane, MD
Innovations in Immunotherapy - Melanoma Systemic Therapies October 27, 2018 Charles L. Bane, MD Melanoma Prognosis Survival at 10 years Stage I: 90% Stage II: 60% Stage III: 40% Stage IV: 10% 2 Indications
More informationBRAF Inhibitors in Metastatic disease. Grant McArthur MB BS PhD Peter MacCallum Cancer Centre Melbourne, Australia
Inhibitors in Metastatic disease Grant McArthur MB BS PhD Peter MacCallum Cancer Centre Melbourne, Australia Disclosures Research Support Pfizer & Cellgene Consultant Provectus Mortality from Melanoma
More informationImmunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania
Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania Overview Background Immunotherapy clinical decision questions
More informationEvolving Treatment Strategies in the Management of Metastatic Melanoma: Novel Therapies for Improved Patient Outcomes. Disclosures
Evolving Treatment Strategies in the Management of Metastatic Melanoma: Novel Therapies for Improved Patient Outcomes Fall Managed Care Forum November 11, 2016 Matthew Taylor, M.D. Disclosures Consulting/Advisory
More informationNew Systemic Therapies in Advanced Melanoma
New Systemic Therapies in Advanced Melanoma Sanjay Rao, MD FRCPC Medical Oncologist (BCCA-CSI) Clinical Assistant Professor, UBC Faculty of Medicine SON Fall Update October 22, 2016 Disclosures Equity
More informationNational Institute for Health and Care Excellence. Single Technology Appraisal (STA)
National Institute for Health and Care Excellence Single Technology Appraisal (STA) Nivolumab for treating advanced (unresectable or metastatic) melanoma At the scoping consultation stage, the scopes for
More informationBRAF Gene Variant Testing To Select Melanoma or Glioma Patients for Targeted Therapy
BRAF Gene Variant Testing To Select Melanoma or Glioma Patients for Targeted Therapy Policy Number: 2.04.77 Last Review: 12/2018 Origination: 4/2013 Next Review: 12/2019 Policy Blue Cross and Blue Shield
More informationLocally Advanced and Metastatic Melanoma. Relevant disclosures 6/23/2018. What is the median survival of metastatic melanoma? Abel D.
Locally Advanced and Metastatic Melanoma Abel D. Jarell, MD, FAAD Adjunct Dartmouth School of Medicine, Hanover, NH Northeast Dermatology Associates, Portsmouth, NH Relevant disclosures What is the median
More informationBest Practices in the Treatment and Management of Metastatic Melanoma. Melanoma
Best Practices in the Treatment and Management of Metastatic Melanoma Philip Friedlander MD PhD Director of Melanoma Medical Oncology Program Assistant Professor Division of Hematology Oncology Assistant
More informationHealthcare Professional. Frequently Asked. Questions. Brochure
YERVOY (ipilimumab) Healthcare Professional Frequently Asked Questions Brochure YERVOY is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. 1 This medicinal product
More informationToxicity of Systemic Melanoma Therapies. Alex Guminski Melanoma Institute Australia Royal North Shore Hospital University of Sydney
Toxicity of Systemic Melanoma Therapies Alex Guminski Melanoma Institute Australia Royal North Shore Hospital University of Sydney Disclosures Advisory Board Novartis, BMS, Sanofi, Pfizer Travel support
More informationWhat's New in Oncodermatopathology: Immunotherapy Reactions
What's New in Oncodermatopathology: Immunotherapy Reactions Emily Y. Chu, M.D., Ph.D. Assistant Professor of Dermatology & Pathology and Laboratory Medicine Hospital of the University of Pennsylvania March
More informationEGFR-TARGETED THERAPIES FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) Pocket Guide
EGFR-TARGETED THERAPIES FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) Pocket Guide The information in this pocket guide is intended as reference material and should not replace clinical judgment or updated
More informationNew Therapeutic Approaches to Malignant Melanoma
2018 Master Class for Oncologists New Therapeutic Approaches to Malignant Melanoma F. Stephen Hodi, M.D. Dana-Farber Cancer Institute, Boston, MA Disclosure I have nothing to disclose. Off Label/Investigational
More informationRashes Not To Be Missed In Children
May 2016 Rashes Not To Be Missed In Children Dr Chan Yuin Chew Dermatologist Dermatology Associates Gleneagles Medical Centre Scope of presentation Focus on rashes May lead to significant morbidity if
More informationTafinlar. Tafinlar (dabrafenib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.04.37 Subject: Tafinlar Page: 1 of 6 Last Review Date: June 19, 2015 Tafinlar Description Tafinlar (dabrafenib)
More informationLiving Beyond Cancer Skin Cancer Detection and Prevention
Living Beyond Cancer Skin Cancer Detection and Prevention Cutaneous Skin Cancers Identification Diagnosis Treatment options Prevention What is the most common cancer in people? What is the most common
More informationCurrent Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology
Current Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology Overview Melanoma incidence and prevention Approach to surgical management of early melanoma Landscape of Advanced Melanoma Therapy
More informationYervoy. Yervoy (ipilimumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.13 Subject: Yervoy Page: 1 of 5 Last Review Date: September 15, 2017 Yervoy Description Yervoy (ipilimumab)
More informationPaediatric Eczema. Dr Manjeet Joshi Consultant Dermatologist 16 th May 2012
Paediatric Eczema Dr Manjeet Joshi Consultant Dermatologist 16 th May 2012 Classification of the principal forms of eczema EXOGENOUS ENDOGENOUS Irritant Allergic contact Photoallergic contact Eczematous
More informationScottish Medicines Consortium
Scottish Medicines Consortium imiquimod 5% cream (Aldara) No. (385/07) Meda Pharmaceuticals Ltd 04 April 2008 The Scottish Medicines Consortium has completed its assessment of the above product and advises
More informationErdheim-Chester disease and Skin issues
Erdheim-Chester disease and Skin issues STÉPHANE BARETE, MD, PHD UNIT OF DERMATOLOGY PITIÉ -SALPÊTRIÈRE HOSPITAL PARIS stephane.barete@aphp.fr Introduction Erdheim-Chester (ECD) is an orphan disease included
More informationTOXICITY RELATED TO IO IN LUNG CANCER
TOXICITY RELATED TO IO IN LUNG CANCER Dr. Jorge A. Alatorre Alexander Head of the Thoracic Oncology Clinic at Instituto Nacional de Enfermedades Respiratorias American British Cowdray Medical Center Mexico
More informationImmunotherapy: Toxicity Management. Dr. Megan Lyle Medical Oncologist Liz Plummer Cancer Care Centre Cairns Hospital
Immunotherapy: Toxicity Management Dr. Megan Lyle Medical Oncologist Liz Plummer Cancer Care Centre Cairns Hospital Disclosures Honoraria and travel support from BMS, MSD, Novartis Advisory board for MSD
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Malignant melanoma: assessment and management of malignant melanoma 1.1 Short title Malignant Melanoma 2 The remit The Department
More informationPhase 1 Study Combining Anti-PD-L1 (MEDI4736) With BRAF (Dabrafenib) and/or MEK (Trametinib) Inhibitors in Advanced Melanoma
Phase 1 Study Combining Anti-PD-L1 (MEDI4736) With BRAF (Dabrafenib) and/or MEK (Trametinib) Inhibitors in Advanced Melanoma Abstract #3003 Ribas A, Butler M, Lutzky J, Lawrence D, Robert C, Miller W,
More informationManaging Checkpoint Inhibitor Toxicities. Megan L. Menon, Pharm.D., BCOP Roswell Park Cancer Institute
Managing Checkpoint Inhibitor Toxicities Megan L. Menon, Pharm.D., BCOP Roswell Park Cancer Institute Approved Indications Ipilimumab Nivolumab Pembrolizumab* Atezolizumab Avelumab Durvalumab Ipi + Nivol
More informationBRAF Genetic Testing to Select Melanoma or Glioma Patients for Targeted Therapy
Medical Policy Manual Genetic Testing, Policy No. 41 BRAF Genetic Testing to Select Melanoma or Glioma Patients for Targeted Therapy Next Review: August 2019 Last Review: July 2018 Effective: August 1,
More informationYervoy. Yervoy (ipilimumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.13 Subject: Yervoy Page: 1 of 4 Last Review Date: March 18, 2016 Yervoy Description Yervoy (ipilimumab)
More informationTreatment and management of advanced melanoma: Paul B. Chapman, MD Melanoma Clinical Director, Melanoma and Immunotherapeutics Service MSKCC
Treatment and management of advanced melanoma: 2018 Paul B. Chapman, MD Melanoma Clinical Director, Melanoma and Immunotherapeutics Service MSKCC Disclosure Paul B. Chapman, MD Nothing to disclose. Off
More informationA View to the Future: The Development of Targeted Therapy for Melanoma. Michael Davies, M.D., Ph.D.
A View to the Future: Science to Survivorship Symposium September 26, 2009 The Development of Targeted Therapy for Melanoma Michael Davies, M.D., Ph.D. Assistant Professor, Melanoma Medical Oncology How
More informationDerm quiz. Go to this link: goo.gl/forms/kchrhmtzl3vfnlv52. bit.ly/2a8asoy. Scan the QR code with your phone
Dermatology quiz Derm quiz Go to this link: goo.gl/forms/kchrhmtzl3vfnlv52 OR bit.ly/2a8asoy OR Scan the QR code with your phone Contents Childhood rashes Pigmented lesions Sun damage Pityriasis References
More informationBRAF Gene Mutation Testing To Select Melanoma or Glioma Patients for Targeted Therapy
BRAF Gene Mutation Testing To Select Melanoma or Glioma Patients for Targeted Therapy Policy Number: 2.04.77 Last Review: 12/2017 Origination: 4/2013 Next Review: 12/2018 Policy Blue Cross and Blue Shield
More informationPTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
More informationUpdate on Immunotherapy in Advanced Melanoma. Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017
Update on Immunotherapy in Advanced Melanoma Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017 1 Outline Adjuvant Therapy Combination Immunotherapy Single
More informationLung Pathway Group Erlotinib in Non-Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Erlotinib in Non-Small Cell Lung Cancer (NSCLC) Indication: NICE TA258 NICE TA162 Locally advanced or metastatic NSCLC as a first line treatment option Positive test for epidermal growth
More informationTargeted Therapies 5/21/2018. Iatrogenic Dermatopathology: When Therapy Goes Wrong
Iatrogenic Dermatopathology: When Therapy Goes Wrong Tammie Ferringer, MD Geisinger Medical Center, Danville, PA tferringer@geisinger.edu I do not have any relevant relationships with industry Targeted
More informationLapatinib (Tyverb ) plus Capecitabine (Xeloda ) Cumbria, Northumberland, Tyne & Wear Area Team
DRUG ADMINISTRATION SCHEDULE Day Drug Daily Dose Route Diluent Rate Days 1 to 21 Days 1 to 14 Lapatinib Capecitabine 1250mg ONCE a day 1000 mg/m 2 twice a day* Oral N/A Continuous BO22-Laptinib-Capecitabine-protocol-CRP10-v1.3
More informationCheckpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health
Checkpoint regulators a new class of cancer immunotherapeutics Dr Oliver Klein Medical Oncologist ONJCC Austin Health Cancer...Immunology matters Anti-tumour immune response The participants Dendritc cells
More informationCombiRT in Metastatic Melanoma Trial
CombiRT in Metastatic Melanoma Trial An open-label, single-arm, phase I/II, multicenter study to evaluate the safety and efficacy of the combination of dabrafenib, trametinib and palliative radiotherapy
More informationIpilimumab in Melanoma
Ipilimumab in Melanoma Indication: Advanced (unresectable or metastatic) melanoma in adults who have received prior therapy LCNDG criteria to be met: Histologically confirmed unresectable stage III or
More informationInhoud. Melanoom anno 2012 Nieuwe therapieën en Follow-up. Gemetastaseerd melanoom. Gemetastaseerd melanoom
Inhoud Melanoom anno 212 Nieuwe therapieën en Follow-up Jeroen Mebis MD PhD Medisch Oncoloog Jessaziekenhuis UHasselt Gemetastaseerd melanoom Gemetastaseerd melanoom Adjuvant beleid Follow-up Voorstel
More informationReview Article Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the Literature
Dermatology Research and Practice Volume 2016, Article ID 5361569, 6 pages http://dx.doi.org/10.1155/2016/5361569 Review Article Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of
More informationNECN CHEMOTHERAPY HANDBOOK PROTOCOL
Nivolumab (Opdivo ) for treatment of advanced melanoma and Renal Cell Cancer (Also advanced/ metastatic NSCLC EMAS patients only -Nov 2016) DRUG ADMINISTRATION SCHEDULE (SINGLE AGENT Day Drug Daily dose
More information6/7/16. Melanoma. Updates on immune checkpoint therapies. Molecularly targeted therapies. FDA approval for talimogene laherparepvec (T- VEC)
Melanoma John A Thompson MD July 17, 2016 Featuring: Updates on immune checkpoint therapies Molecularly targeted therapies FDA approval for talimogene laherparepvec (T- VEC) 1 Mechanism of ac-on of Ipilimumab
More informationTeledermatology Paediatric eczema. Dr Carolyn Charman Consultant Dermatologist Royal Devon and Exeter Hospital
Teledermatology Paediatric eczema Dr Carolyn Charman Consultant Dermatologist Royal Devon and Exeter Hospital NHS e-referral teledermatology Rapid access to diagnosis / management advice from local integrated
More informationManagement of Immune Checkpoint Inhibitor Related Toxicities
Management of Immune Checkpoint Inhibitor Related Toxicities Katie Wolfram, PharmD Clinical Pharmacist, Oncology Memorial Hospital of South Bend A Webinar for HealthTrust Members November 12, 2018 Disclosures
More informationUpdates in Metastatic Melanoma
SCSHP 214 Annual Meeting Updates in Metastatic Melanoma LeAnn B. orris, PharmD, BCPS, BCOP Assistant Professor South Carolina College of Pharmacy Background Estimated 76,69 new cases in 213 Increasing
More informationPembrolizumab 200mg Monotherapy
Pembrolizumab 200mg This regimen supercedes NCCP Regimen 00347 Pembrolizumab 2mg/kg as of September 2018 due to a change in the licensed dosing posology. INDICATIONS FOR USE: INDICATION ICD10 Regimen Code
More informationDisclosures. Melanoma and Non melanoma Skin Cancer: What You Need to Know. I have no conflicts of interest to disclose
Disclosures Melanoma and Non melanoma Skin Cancer: What You Need to Know I have no conflicts of interest to disclose Lindy P. Fox, MD Associate Professor Director, Hospital Consultation Service Department
More informationPembrolizumab: First in Class for Treatment of Metastatic Melanoma
Section Editors: Christopher J. Campen and Beth Eaby-Sandy Pembrolizumab: First in Class for Treatment of Metastatic Melanoma CARRIE BARNHART, PharmD From Billings Clinic Cancer Center, Billings, Montana
More informationCorporate Medical Policy
Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer
More informationMelanoma. Il parere dell esperto. V. Ferraresi. Divisione di Oncologia Medica 1
Melanoma Il parere dell esperto V. Ferraresi Divisione di Oncologia Medica 1 MELANOMA and ESMO 2017.what happens? New data and updates ADJUVANT THERAPY with CHECKPOINT INHIBITORS (CA209-238 trial) AND
More informationUpdate on Melanoma Treatment. Tara C Mitchell, MD
Update on Melanoma Treatment Tara C Mitchell, MD Overview Immune therapy update Targeted therapy update New concepts in treating melanoma What is the immune system? A complex network of protective cells
More informationThe management of chronic urticaria in primary care for adults and children
The management of chronic urticaria in primary care for adults and children September Version 2.0 This supersedes version 1.0 Review due in September 2019 Document location DOCUMENT CONTROL Copies of this
More informationUpdates in the Management of Epidermal Growth Factor Receptor (EGFR) Inhibitors- Induced Skin Rash. Outline. Signal Transduction
Updates in the Management of Epidermal Growth Factor Receptor (EGFR) Inhibitors- Induced Skin Rash Siu-Fun Wong, PharmD, FASHP, FCSHP Associate Professor of Pharmacy Practice Western University of Health
More informationMEK/BRAF inhibitors and the implications on patients and health care providers
MEK/BRAF inhibitors and the implications on patients and health care providers Tara McKeown NP Paediatric Neuro Oncology Hospital for Sick Children Adjunct Lecturer, Lawrence S. Bloomberg, Faculty of Nursing,
More information